BioNTech Results Presentation Deck

BNT311: Phase 1 / 2a - Pharmacodynamics Modulation of peripheral pharmacodynamic markers A ● ● 18 100.0- 50.0- 20.0 10.0- 5.0- 2.0- 1.0- 0.5 IFN-Y p=0.021 Lower Higher doses doses B IP-10 Wilcoxon-Mann-Whitney test. IFN, interferon; IP-10, interferon-gamma-inducible protein 10. p=0.035 Lower Higher doses doses C Proliferating (Ki67+) CD8 T cells 20.0- 10.0 5.0- 2.0 1.0- 0.5 8. Lower doses p=0.024 8 * Higher doses Data extraction: June 26, 2020. Maxim al fold-change from baseline measured during cycle 1. Lower doses correspond to dose levels ≤200 mg and higher doses correspond to dose levels 2400 mg. D Proliferating (Ki67+) effector memory CD8 T cells p=0.005 20 10- Pharmacological activity was observed across a broad range of dose levels Increased levels of peripheral IFN-g and IP-10, increased frequency of proliferating (Ki67+) total CD8 and effector memory CD8+ T cells were observed Lower Higher doses doses BIONTECH

View entire presentation